Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.

Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Abstract Text:

Joshua Caballero,Michael Hitchcock,Douglas Scharre,David Beversdorf,Milap C Nahata,

BACKGROUND: In addition to cognitive decline, 30% to 40% of patients with Alzheimer's disease (AD) experience concomitant psychiatric and behavioral complications, such as hallucinations, delusions, and aggression. Atypical antipsychotics (AAs) are used to treat psychosis and aggressive behaviors in these patients; however, data regarding their early effects on cognition are conflicting. Based on a literature search, the cognitive effects of long-term treatment with AAs in outpatients with AD have not been studied. OBJECTIVE: The aim of this study was to describe and compare the rate of cognitive decline with longterm AA use in adult patients with AD receiving concomitant treatment with cholinesterase inhibitors. METHODS: This study was conducted at the Department of Neurology, The Ohio State University, Columbus, Ohio. Data were collected from the charts of adult outpatients who (1) received care at Memory Disorders Clinic, Columbus, Ohio, between April 2003 and June 2005; (2) were aged > or =55 years with a diagnosis of mild to severe definite or probable AD; (3) received an AA for > or =6 months or did not receive any AA; and (4) received a cholinesterase inhibitor during the entire evaluation period. Cognitive function, as measured using the Mini-Mental State Examination (MMSE), was compared between those who received AA treatment and those who did not. The end point was the rate of decline in cognitive function, defined as annualized change in mean MMSE score from baseline to the end of follow-up. RESULTS: Ninety-two outpatients were included in the final analysis (67 women, 25 men; mean age, 72.4 years). Thirty-four patients received treatment with an AA for 6 > or =months (mean duration of treatment, 421 days) and 58 did not receive any AA treatment. Quetiapine (mean dose, 67 mg/d) was prescribed to 28 (82 %) of the patients receiving an AA. The AAs were prescribed for psychosis (15 [44%] patients), psychosis/agitation (11 [32%]), and agitation/aggression (8 [24%]). The baseline mean MMSE scores in patients receiving and not receiving an AA were 14.65 and 17.88, respectively (P = 0.021), with mean (SD) annual rates of cognitive decline of 3.03 (1.84) and 2.24 (1.27), respectively (P = NS). CONCLUSION: The results from this retrospective study of data from a small, selected group of outpatients with AD did not find a significant difference in the rate of cognitive decline between those who received an AA for > or =6 months and those who did not.

Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Publishing Authors By Initials

J Caballero,M Hitchcock,D Scharre,D Beversdorf,MC Nahata,

For similar investigative techniques: epidemiologic methods: epidemiologic study characteristics as topic: epidemiologic studies: case-control studies: retrospective studies research abstracts see: investigative techniques: epidemiologic methods: epidemiologic study characteristics as topic: epidemiologic studies: case-control studies: retrospective studies research

PUBMED ID PMID:

MEDLINE DATE:

Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Clinical therapeutics

VOLUME: 28

Page Numbers: 1695-700

Journal Abbreviation:

ISSN: 0149-2918

DAY: 3

MONTH: Oct

YEAR: 2006

Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7706726

Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Keywords Mesh Terms:

KEYWORDS: Retrospective Studies

MESH TERMS: complications

Chemical & Substance for Abstract: Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Information

Substance Name: Antipsychotic Agents

Registry Number: 0

Grant and Affiliation Information for Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.

AFFILIATION: College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA.

Country: United States

AGENCY: United States NINDS

GRANT: NS045222

ACRONYM: NS

MEDLINETA: Clin Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study Related Publications

• A comparative review of conventional and lipid formulations of amphotericin B.
• A programme to enrich undergraduate education through participation in clinical pharmacy research.
• Advances in paediatric pharmacotherapy.
• Aerosolized dornase alpha (rhDNase) in cystic fibrosis.
• Clinical research by pharmacists.
• Clinical uses of dexmedetomidine in pediatric patients.
• Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.
• Do statins slow down Alzheimer's disease? A review.
• Drug administration errors in pediatric patients.
• Drug combinations in India.
• Electro-optic detection of continuous-wave mid-infrared radiation.
• Electro-optic detection of femtosecond electromagnetic pulses by use of poled polymers.
• Extended stability of iobenguane under simulated clinical conditions.
• Extraordinary optical transmission through metallic films perforated with aperture arrays having short-range order.
• Generation of broadband radially polarized terahertz radiation directly on a cylindrical metal wire.
• Guidelines for antimicrobial prophylaxis.
• Lack of predictability of chloramphenicol toxicity in paediatric patients.
• Long-term effects of antidepressants on cognition in patients with Alzheimer's disease.
• Nonlinear optical generation and detection of ultrashort electrical pulses in transmission lines.
• Paediatric drug therapy. I--Medication use in hospitalized patients.
• Paediatric drug therapy. II--Drug administration errors.
• Pharmacotherapy of lower limb diabetic ulcers.
• Planar plasmonic terahertz guided-wave devices.
• Plasma concentrations of morphine in children with chronic pain--comparison of controlled release and regular morphine sulphate tablets.
• Prospective evaluation of ten methods for estimating creatinine clearance in children with varying degrees of renal dysfunction.
• Recent advances in the treatment of otitis media.
• Simultaneous measurement of chloramphenicol sodium succinate and chloramphenicol in presence of furosemide in plasma and urine.
• Teaching paediatric pharmacotherapy at colleges of pharmacy in the United States and Canada.
• Tips for writing and publishing an article.
• Variability in clinical pharmacology of drugs in children.